S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
OTCMKTS:SRNEQ

Sorrento Therapeutics (SRNEQ) Stock Price, News & Analysis

$0.10
+0.06 (+153.85%)
(As of 02/23/2024 ET)
Today's Range
$0.03
$0.10
50-Day Range
$0.02
$0.16
52-Week Range
$0.00
$0.42
Volume
577,229 shs
Average Volume
579,814 shs
Market Capitalization
$54.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SRNEQ stock logo

About Sorrento Therapeutics Stock (OTCMKTS:SRNEQ)

Sorrento Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company specializes in developing antibody-based therapies for cancer, autoimmune diseases, and chronic pain. Sorrento Therapeutics was founded in 1989 and has since grown into a  player in the biopharmaceutical industry, focusing on developing innovative and personalized therapies for patients.

The management team at Sorrento Therapeutics is led by Dr. Henry Ji, who serves as the company's Chairman and CEO. Dr. Ji has over 20 years of experience in the biopharmaceutical industry and has played a vital role in developing innovative Sorrento Therapeutics therapies. Other notable team members are Mike Royal, Chief Medical Officer, who has over 20 years of clinical development experience and Dr. Robert D. Allen, who has over 15 years of biotechnology industry research and preclinical development experience. 

Over the past few years, Sorrento Therapeutics has reported relevant growth in revenue. However, the company has also reported significant losses increasing year over year. The company's debt levels have varied dramatically, with assets and liabilities increasing year over year. Sorrento Therapeutics has undergone substantial changes in ownership over the past few years, with several prominent investors increasing their stakes in the company. Sorrento Therapeutics' valuation metrics align with industry peers, with a price-to-book ratio near industry averages. However, the company's price-to-earnings ratio is currently negative, typical for clinical-stage biopharmaceutical companies that have yet to reach profitability. Sorrento Therapeutics stock has been volatile in recent years, with significant price movements and changes in trading volume. The company's stock price has steadily declined over the past five years.

The biopharmaceutical industry is highly competitive, with many large, established companies and smaller, innovative players like Sorrento Therapeutics. High research and development spending levels, lengthy regulatory approval processes, and significant intellectual property protections characterize the industry. Sorrento Therapeutics faces competition from established players such as Pfizer, Merck, and Bristol-Myers Squibb, as well as smaller biotechs developing similar antibody-based therapies.

Sorrento Therapeutics has several potential growth opportunities, including developing its proprietary antibodies and other therapies for treating cancer, autoimmune diseases, and chronic pain. The company is also exploring partnerships and collaborations with other companies in the biopharmaceutical industry to help accelerate the development of its pipeline of therapies. Additionally, Sorrento Therapeutics is expanding into new markets, focusing on Asia, with significant demand for innovative treatments.

The biopharmaceutical industry is highly regulated, and Sorrento Therapeutics may face challenges in obtaining regulatory approval for its therapies. The company's financial performance has also been volatile, with significant losses reported in recent years. Sorrento Therapeutics will need to continue investing heavily in research and development to maintain its competitive position in the industry, which may strain the company's financial resources. In addition, the biopharmaceutical industry is subject to significant geopolitical and regulatory risks, which could impact Sorrento Therapeutics' operations and growth prospects.

SRNEQ Stock Price History

SRNEQ Stock News Headlines

Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Sorrento Therapeutics Inc. (SRNEQ)
Sorrento Therapeutics Inc (SRNEQ)
See More Headlines
Receive SRNEQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/25/2024
Next Earnings (Estimated)
3/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:SRNEQ
Employees
949
Year Founded
N/A

Profitability

Net Income
$-572,840,000.00
Net Margins
-852.82%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$62.84 million
Book Value
($0.05) per share

Miscellaneous

Free Float
536,948,000
Market Cap
$54.58 million
Optionable
Not Optionable
Beta
2.49
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Henry H. Ji Ph.D. (Age 60)
    Chairman, President & CEO
    Comp: $2.03M
  • Mr. Brian Cooley
    Senior Vice President of Corporate Communications & Lymphatic Drug Development BU
  • Dr. Michael A. Royal J.D. (Age 70)
    M.D., MBA, SVP & Chief Medical Officer
    Comp: $557.04k
  • Dr. Alexis Nahama D.V.M.
    Senior Vice President of Neurotherapeutics BU
  • Dr. Mark R. Brunswick
    Senior Vice President of Regulatory Affairs
  • Dr. Shawn Sahebi Ph.D.
    Senior Vice President of Commercial Operations
  • Dr. Xiao Xu M.D.
    President of ACEA














SRNEQ Stock Analysis - Frequently Asked Questions

How have SRNEQ shares performed in 2024?

Sorrento Therapeutics' stock was trading at $0.1235 at the beginning of the year. Since then, SRNEQ stock has decreased by 19.8% and is now trading at $0.0990.
View the best growth stocks for 2024 here
.

When is Sorrento Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our SRNEQ earnings forecast
.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNEQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SRNEQ) was last updated on 2/25/2024 by MarketBeat.com Staff